Results: Ninety-one patient cases (76.9% female) with 105 events were retrieved. Time to onset varied from 2 months to 14 years, and in 31.9% of patients the event occurred within 2 years of treatment initiation. Seven patients had a fatal outcome (five were secondary to other causes and two reported insufficient information). Forty-four patients recovered, 32 patients had not recovered at the time of the report, and in eight cases outcome was either not reported or unknown. Treatment was discontinued in 84.6% (77/91) of patients. In 67% (61/91) of patients, the reporter suspected a causal association between treatment and TMA/TTP-HUS. 
RESULTS
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In total, 91 serious patient cases were retrieved with 105 serious events of TMA, TTP, and HUS 
DISCUSSION
Practice guidelines for TTP and TMA address the difficulties in diagnosis of the disorders due to overlap with autoimmune disease and state that drugs (including quinine, estrogen-containing medications, and pegylated IFN used to treat hepatitis C) appear to be responsible for\15% of all TTP cases [12] . Nevertheless, no fixed guidelines exist for TMA cases associated with sc IFN b-1a due to the rarity of the disorder and, following a recent cluster of patient reports in South Scotland [11] , it was deemed that research was required to identify any differences in incidence rates associated with the introduction of a HSA-free formulation of sc 
